Merck KGaA Share Price – Live Data and Analysis
Merck KGaA, the Darmstadt-based pharmaceutical and life sciences company, continues to attract investor attention as its share price reflects broader market dynamics in the European healthcare sector. Trading on Xetra under the ticker MRK (or MRCG in certain listings), the stock represents one of Germany’s most prominent listed companies in the pharmaceutical industry.
Investors tracking MRK.DE frequently consult multiple data sources to gauge real-time performance, given that quotes may vary slightly between platforms. The company’s listing on the Frankfurt Stock Exchange makes it accessible to both institutional and retail shareholders seeking exposure to European pharma markets.
This comprehensive overview covers current pricing, historical performance, key financial metrics, and analyst perspectives to help understand what drives Merck KGaA’s valuation on the German market.
What is the Current Merck KGaA Share Price?
As of the latest available data, Merck KGaA shares trade at approximately 111.85 EUR on the Xetra exchange. Price quotes may differ slightly between platforms, with some sources showing 109.55 EUR depending on data latency. The stock experienced a decline of 1.33% over the past 24 hours according to primary market data.
Stock prices fluctuate continuously during trading hours. Minor quote variations between platforms (such as 111.85 EUR versus 109.55 EUR) reflect differences in data feed timing. Investors should verify current pricing on official exchange platforms for execution accuracy.
Key Market Insights
- Year-to-date performance shows gains of approximately 2.65%, indicating modest recovery from earlier 2026 lows
- The stock has declined 36.07% over the past twelve months, reflecting significant pressure on pharma valuations
- With a beta of 0.75, Merck KGaA demonstrates lower volatility compared to the broader market
- The shares float stands at 129.24 million, providing reasonable liquidity for investors
- Recent closing prices ranged from 125.85 EUR (January 29) to 128.45 EUR (January 27), showing intra-week variation
- Fair value analysis indicates approximately 16.2% upside potential, outpacing the sector average of 6.2%
- The company recently announced a collaboration with CEPI to improve Ebola vaccine accessibility in low-income countries
Quick Reference: Core Metrics
| Metric | Value | Notes |
|---|---|---|
| Ticker Symbol | MRK / MRCG | Xetra / Frankfurt |
| Exchange | Xetra (Frankfurt Stock Exchange) | Primary listing |
| 52-Week High | 151.7 EUR | Within current range |
| 52-Week Low | 100.7 EUR | Recent multi-year bottom |
| P/E Ratio (TTM) | 16.50 | Below sector average of 18.5x |
| Dividend Yield | 2.01% | 2025 estimate: 1.84% |
| EPS (TTM) | 6.60 EUR | Basic earnings per share |
How Has Merck KGaA Stock Performed Recently?
Recent trading sessions reveal a stock navigating through challenging market conditions in the European pharmaceutical sector. The share price has shown mixed signals across different time horizons, with short-term volatility contrasting against longer-term weakness.
Short-Term Performance Trends
Over the past week, the stock recorded gains of approximately 2.38%, while the monthly performance showed a more modest increase of 1.39%. This short-term resilience masks deeper concerns, as the stock remains substantially below levels seen twelve months prior.
Intra-day data indicates volatility around 1.47%, suggesting active trading despite the stock’s beta reading of 0.75 (indicating below-market price sensitivity). This discrepancy between calculated beta and observed volatility reflects the company’s exposure to sector-specific news flow and broader market sentiment shifts.
Where is Merck KGaA Stock Traded?
Merck KGaA trades primarily on the Xetra electronic trading platform, which serves as the central venue for German equities. The ticker symbol MRK identifies the stock on this exchange, though alternative listings use MRCG for certain clearing and settlement purposes. International investors can access the shares through their local brokers with Xetra connectivity, making it one of Europe’s most internationally accessible German listings.
For those interested in technical analysis indicators such as MACD, RSI, or moving averages, specialized platforms provide interactive charting capabilities that supplement official exchange data. These tools can help identify potential entry and exit points based on historical price patterns.
To access real-time Merck KGaA quotes and technical charts, investors typically use platforms like TradingView, which aggregates data directly from Xetra. The official Frankfurt Stock Exchange website also provides consolidated pricing information for MRK.DE.
What Are Merck KGaA’s Key Financial Metrics?
Understanding Merck KGaA’s fundamental valuation requires examining the core financial indicators that drive investor decisions. The company operates across pharmaceuticals and life sciences, generating revenue streams that support its market valuation.
Valuation Metrics
The trailing twelve-month P/E ratio of 16.50 positions Merck KGaA below the sector average of 18.5x, suggesting the market prices the stock at a discount relative to peers. Forward estimates project the P/E to expand to approximately 19.1x for 2025 and 18.8x for 2026, implying expected earnings compression or anticipated growth.
Additional valuation tools reveal further insights. The PEG ratio stands at 1.77, the price-to-book ratio at 1.7x (versus sector 4.1x), and price-to-sales at 2.2x (sector 3.2x). These metrics collectively suggest that while the stock trades at a discount to sector averages, the PEG ratio above 1.0 indicates some premium is priced into future growth expectations.
Income and Profitability
Fiscal year data shows net income of 2.78 billion EUR against total revenue of 21.16 billion EUR, translating to a net margin that reflects the capital-intensive nature of pharmaceutical operations. The company continues investing heavily in research and development to maintain its competitive positioning across life sciences applications.
Dividend Considerations
Merck KGaA maintains a dividend policy supporting the indicated yield of 2.01%, with estimates suggesting 1.84% for 2025 and 1.92% for 2026. These projections indicate relatively stable shareholder returns despite market pressure on the share price. Income-focused investors often monitor dividend yield trends alongside capital appreciation potential when evaluating total return profiles.
Data sources show minor variations in market capitalization figures. TradingView reports approximately 47.63 billion EUR (up 0.83% weekly), while MarketScreener indicates 54.72 billion EUR. Investors should note these differences may reflect different calculation methodologies, share counts, or data timestamps. Cross-referencing multiple authoritative sources remains advisable before making investment decisions.
What Do Analysts Say About MRK.DE?
Analyst coverage of Merck KGaA provides institutional perspective on fair value and expected performance. Price target ranges offer insight into professional sentiment regarding the stock’s near-term and medium-term prospects.
Price Targets and Forecasts
Current analyst consensus places maximum price targets at 188.00 EUR, contrasting with minimum targets around 100.00 EUR. This substantial range reflects genuine uncertainty about the company’s ability to navigate competitive pressures in its core pharmaceutical markets. The upside potential from current levels stands at approximately 42.4% against maximum targets.
Fair value analysis suggests approximately 16.2% upside from present prices, notably exceeding the sector average fair value upside of 6.2%. This differential indicates analysts perceive greater value opportunity in Merck KGaA compared to pharmaceutical sector peers.
Factors Influencing Merck KGaA Share Price
Several interconnected factors shape investor sentiment toward MRK.DE. The pharmaceutical sector faces ongoing pricing pressures across European markets, where regulatory frameworks increasingly scrutinize drug costs. Simultaneously, competition from generic manufacturers and biosimilar developers threatens revenue streams from established products.
The company’s life sciences division, serving pharmaceutical research and manufacturing clients, provides diversification that partially offsets drug pipeline uncertainties. Recent strategic initiatives, including the January 2026 partnership with CEPI for Ebola vaccine distribution, demonstrate commitment to global health applications that may support long-term revenue diversification.
Currency dynamics also influence results, as the company’s international operations generate revenues across multiple regions. Exchange rate movements between the euro and other major currencies affect translated earnings when reported in EUR.
Price History and Historical Context
Examining Merck KGaA’s historical price trajectory provides essential context for evaluating current valuation levels and understanding how investor sentiment has evolved over time.
Historical Highs and Lows
- All-time high: 231.5 EUR recorded on December 30, 2021, representing peak enthusiasm for post-pandemic pharmaceutical positioning
- 52-week range: 100.7 EUR (low) to 151.7 EUR (high), reflecting substantial decline from historical peaks
- 5-year perspective: Low of 100.7 EUR represents the bottom of the recent five-year trading range
- 10-year perspective: The 10-year low stands at 70.68 EUR, demonstrating that current levels remain significantly above long-term troughs
Recent Annual Closing Prices
Historical closing data from official company records (adjusted for the 2014 share split) reveals the trajectory of decline. The 2024 trading range of 137.85 EUR to 175.85 EUR has given way to further weakness in early 2026, with the stock testing lower support levels not seen in several years.
The 2022 closing range of 156.10 EUR to 222.90 EUR and 2023’s 135.45 EUR to 201.10 EUR demonstrate the progressive compression of the trading range as bear market conditions intensified. Current prices near 111 EUR represent a contraction below even the recent lows established during the initial pandemic sell-off period.
What Remains Clear and Uncertain About Merck KGaA?
Investors evaluating Merck KGaA should distinguish between established facts supported by company disclosures and financial data versus factors subject to market interpretation or future uncertainty.
| Established Information | Factors Subject to Uncertainty |
|---|---|
| Current trading price approximately 111 EUR on Xetra | Actual timing and magnitude of any price recovery |
| Market capitalization between 47-55 billion EUR | Future earnings trajectory and profit margins |
| Dividend yield approximately 2% | Potential dividend policy changes during downturns |
| P/E ratio below sector average | Competitive threats from generics and biosimilars |
| 52-week low of 100.7 EUR | Regulatory decisions affecting key products |
| Revenue 21.16B EUR, Net Income 2.78B EUR | Currency impacts on international revenues |
The distinction between confirmed data and forward-looking uncertainty helps investors calibrate their risk assessment. While fundamental metrics like revenue and net income derive from audited financial statements, price targets and growth projections reflect analyst judgment and are inherently probabilistic.
Sources and Data References
This analysis draws upon multiple authoritative financial data sources to ensure accuracy and comprehensiveness. Real-time pricing data comes primarily from Xetra trading screens aggregated through financial platforms.
“Data reflects market close or delayed quotes; prices fluctuate throughout trading sessions. Users should verify real-time pricing on official exchange platforms before making investment decisions.”
— TradingView, Xetra/MRK.DE Market Data
Official company filings and investor relations materials from Merck KGaA provide historical closing prices and corporate announcements. The company’s investor relations website maintains long-term price charts dating to the 2014 share split adjustment, offering verified historical context for current valuations.
“Historical closes (Xetra, adjusted for 2014 split) provide verified reference points for investors assessing long-term performance.”
— Merck Group Investor Relations
Summary: Understanding Merck KGaA Share Price Dynamics
Merck KGaA trades at approximately 111.85 EUR on the Frankfurt Stock Exchange, representing a substantial decline from its December 2021 all-time high of 231.5 EUR. The stock’s 52-week range of 100.7 to 151.7 EUR highlights the volatility investors have experienced, with current prices near the lower end of this range.
Key financial metrics including the P/E ratio of 16.50 (below the 18.5x sector average), dividend yield around 2%, and EPS of 6.60 EUR provide quantitative context for valuation assessment. The market capitalization between 47-55 billion EUR reflects uncertainty in calculation methodologies across different data providers.
Analyst sentiment suggests upside potential ranging from 16% to 42% depending on assumptions, with the stock trading at a discount to sector averages on several valuation metrics. Factors including competitive pressures, regulatory developments, and currency movements continue influencing investor sentiment toward this major European pharmaceutical listing.
For additional context on how certain health conditions may present themselves, see our guide to Cancer Red Spots on Skin. Understanding broader health topics can provide useful background for investors evaluating pharmaceutical sector opportunities.
Frequently Asked Questions
Where is Merck KGaA stock traded?
Merck KGaA trades on the Xetra electronic trading platform under ticker symbols MRK or MRCG. Xetra serves as the primary venue for German equities trading, operated through the Frankfurt Stock Exchange infrastructure.
What is the difference between Merck & Co and Merck KGaA?
These are separate companies with no direct affiliation. Merck KGaA is a German pharmaceutical and life sciences company headquartered in Darmstadt. Merck & Co is an American pharmaceutical company, originally related but now entirely independent following a 1917 separation. The two companies operate independently with separate stock listings and business strategies.
Does Merck KGaA pay dividends?
Yes, Merck KGaA maintains a dividend policy with an indicated yield of approximately 2.01%. Estimated yields for 2025 and 2026 stand at 1.84% and 1.92% respectively, suggesting relatively stable shareholder returns despite market challenges.
What is the 52-week high and low for Merck KGaA?
The 52-week range spans from 100.7 EUR (low) to 151.7 EUR (high). These levels represent significant decline from the all-time high of 231.5 EUR achieved in December 2021, with the current price hovering near the lower end of the annual range.
What factors affect Merck KGaA share price?
Multiple factors influence MRK.DE valuation including pharmaceutical sector pricing pressures, regulatory decisions on drug approvals and reimbursements, competition from generic manufacturers, currency fluctuations affecting international revenues, and general market sentiment toward healthcare stocks.
What is the analyst consensus for Merck KGaA?
Analyst price targets range from 100.00 EUR (minimum) to 188.00 EUR (maximum), with consensus suggesting approximately 16.2% upside from current levels. This compares favorably to the sector average fair value upside of 6.2%, indicating potential relative outperformance opportunities.
What is Merck KGaA’s market capitalization?
Market capitalization estimates vary between approximately 47.63 billion EUR and 54.72 billion EUR depending on data source and calculation methodology. The float consists of approximately 129.24 million shares, with the share price multiplied by share count determining total market value.
How has Merck KGaA performed year-to-date?
Year-to-date performance shows gains of approximately 2.65%, with the past month adding 4.40% and three-month performance reaching 10.88%. However, the stock remains down 36.07% over the trailing twelve months, reflecting longer-term weakness despite recent recovery attempts.
More related posts
Online Pendulum Yes or No: How to Use & Accuracy
Millie Bobby Brown Baby Adoption: Latest Details
Derry City vs Shamrock Rovers: Prediction, H2H, Live Stream
NASA Artemis Rocket Launch – Schedule, Live Stream and Expectations
Munster v La Rochelle TV: Channel, Stream & Kick-Off Time
Coming 2 America: Review, Plot Gaps, and Where to Stream
How to Clean Stainless Appliances: Streak-Free Guide
